These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24851042)

  • 1. Linagliptin: from bench to bedside.
    Doupis J
    Drug Des Devel Ther; 2014; 8():431-46. PubMed ID: 24851042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of linagliptin for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Clin Ther; 2012 May; 34(5):993-1005. PubMed ID: 22440191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.
    von Websky K; Reichetzeder C; Hocher B
    Vasc Health Risk Manag; 2013; 9():681-94. PubMed ID: 24204157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
    Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
    Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
    Ohmura T; Hayashi N; Encinas J
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
    [No Abstract]   [Full Text] [Related]  

  • 10. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Deeks ED
    Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
    J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
    Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
    Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
    Lajara R
    Expert Opin Pharmacother; 2012 Dec; 13(18):2663-71. PubMed ID: 23137412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.
    Groop PH; Cooper ME; Perkovic V; Emser A; Woerle HJ; von Eynatten M
    Diabetes Care; 2013 Nov; 36(11):3460-8. PubMed ID: 24026560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.